期刊文献+

C-erbB2、c-myc和CCND1 mRNA联合检测在乳腺癌诊断中的应用 被引量:4

Combined detection of C-erbB2,c-myc and CCND1 mRNA levels in diagnosis of breast cancer
下载PDF
导出
摘要 目的建立荧光定量聚合酶链反应(FQ-PCR)法检测C-erbB2、核内原癌基因(c-myc)和细胞周期蛋白D1(CC-ND1)mRNA水平,探讨其联合检测在乳腺癌诊断和治疗监测中的应用。方法建立FQ-PCR法,并以β2-微球蛋白为内对照测定15名健康女性体检者(正常对照组)、30例良性乳腺疾病患者(良性乳腺疾病组)和121例乳腺癌患者(乳腺癌组)外周血中C-erbB2、c-myc和CCND1的mRNA水平。结果 C-erbB2、c-myc和CCND1的mRNA水平在正常对照组和良性乳腺疾病组间差异无统计学意义(P>0.05),乳腺癌组均高于前两组(P<0.05),β2-微球蛋白三组间差异无统计学意义(P>0.05);三种mRNA联合检测的阳性率高于单个mRNA的检测。结论 FQ-PCR技术可快速定量检测C-erbB2、c-myc和CCND1的mR-NA,三者联合检测可有效提高对乳腺癌诊断的阳性率。 Objective To evaluate the clinical application of fluorescent quantification polymerase chain reaction(FQ-PCR) for combined detection of C-erbB2,c-myc and CCND1 mRNA levels in breast cancer.Methods We used β_2-microprotein mRNA as internal control,four mRNA in peripheral blood samples from 15 health women,30 patients with benign breast disease and 81 patients with breast carcinoma were detected by FQ-PCR.Results While no significant difference in four mRNA levels was found between normal controls and benign breast disease group(P0.05).Three mRNA levels in breast cancer group were higher than those in the other groups(P0.05).No difference was found in β_2-microglobin among three groups(P0.05).The sensitivity of three mRNA levels by combined detection was higher than that of single gene detection.Conclusions FQ-PCR method is better for detecting C-erbB2 and c-myc and CCND1 mRNA levels for its sensitivity and specificity.The sensitivity of diagnosis for breast cancer can be improved by combined detection.
出处 《实用医院临床杂志》 2011年第5期21-23,共3页 Practical Journal of Clinical Medicine
基金 四川省杰出青年基金资助项目(编号:2007-5-345)
关键词 荧光定量聚合酶链反应 C-ERBB2 原癌基因 细胞周期蛋白 乳腺癌 Fluorescent quantification polymerase chain reaction C-erbB2 Proto-oncogene Cyclin Breast cancer
  • 相关文献

参考文献7

  • 1杨金巧,陈琳,幸天勇.乳腺癌中C-erbB2癌基因与雌、孕激素受体和PS2的关系及其预后意义[J].四川大学学报(医学版),2004,35(3):334-336. 被引量:36
  • 2Revillion F, Hormez L, Peyrat JP. Quantification of C-erbB2 gene expression in breast cancer by competitive PT-PCR [ J ]. Clin Chem, 1997,43:2114-2220. 被引量:1
  • 3Bostick PJ, Chatterjee S, Chi DD, et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph modes and blood of breast cancer patients [J]. J Clin Oncol,1998,16(8):2632-2640. 被引量:1
  • 4Mitas M, Mikhitarian K, Waiters C, et al. Quantitative real time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel[ J]. Int J Cancer,2001,93 (2) :162-171. 被引量:1
  • 5Bae JW, Choi KH, Kim HG, et al. The detection of circulating breast cancer ceils in peripheral blood by reverse transcriptase-polymearse chain reaction [ J ]. J Korean Med Ser,2000,15 ( 2 ) : 194-198. 被引量:1
  • 6Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction[ J]. Anal Biocbem, 1987,162 ( 1 ) : 156-160. 被引量:1
  • 7金丕焕.医用统计方法[M].上海:上海医科大学出版社,1992.208-214. 被引量:30

二级参考文献10

  • 1Dahiya R, Deng G. Molecular prognostic markers in breast cancer. Breast Cancer Res &amp;Treat,1998;52(1-3):185. 被引量:1
  • 2Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survivalwith amplification of the HER-2/neu oncogene.Science,1987;235(4785):177. 被引量:1
  • 3Kallioniemi OP. Association of C-erbB2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor longterm survival in breast cancer. Int J Cancer,1991;49(5):650. 被引量:1
  • 4Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of C-erbB2 expression in breast cancer. J Surg Oncol,2002;79(4):216. 被引量:1
  • 5Ring AE, Ellis PA. Predictors of response to systemic therapy in breast cancer. Forum,2002;12(1):19. 被引量:1
  • 6Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech,2002;59(2):102. 被引量:1
  • 7Revillion F, Bonneteree J, Peyrat JP. ErbB-2 oncogene in human breast cancer and its clinical significance. Eur J Cancer,1998;34(6):791. 被引量:1
  • 8Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Annals of Oncol,2001;12(suppl):s35. 被引量:1
  • 9阚秀,薛卫成.乳腺癌中PS_2基因与雌激素及孕激素受体[J].中华肿瘤杂志,1998,20(3):237-239. 被引量:23
  • 10罗扬.Herceptin治疗HER-2过度表达乳腺癌的现状[J].国外医学(肿瘤学分册),2002,29(2):126-128. 被引量:2

共引文献56

同被引文献43

  • 1周洁,李华仁,张锦,权莉.p53、rasp21及C-myc癌基因蛋白在胃癌中的表达及分布特征[J].解放军医学杂志,2005,30(11):1009-1011. 被引量:5
  • 2李传芬,荆文,杜会芹,陈苏,张会亮,李云龙.调控胞质分裂的中心体相关蛋白Cep55[J].生命的化学,2006,26(6):487-490. 被引量:2
  • 3Lin Y,Lin S,Watson M,et al. A gene expression signature that predictsthe therapeutic response of the basai-like breast cancer to neoadjuvantchemotherapy. Breast Cancer Res Treat,2010,123 :691-699. 被引量:1
  • 4Song LB,Zeng MS,Liao WT,et al. Bmil is a novel molecular marker ofnasopharyngeal carcinoma progression and immortalizes primary humannasopharyngeal epithelial cells. Cancer Res,2006,66 :6225-6232. 被引量:1
  • 5Kapa AV,Jeffery SS,Lanferod A,et al. Discovery and validation of breastcancer subtypes. BMC Genomics,2006,7:231. 被引量:1
  • 6Ahmad A,Wang Z,Kong D,et al. FoxMl down-regulation leads to inhibi-tion of proliferation,migration and invasion of breast cancer cells throu^ithe modulation of extra-cellular matrix degrading factors. Breast CancerRes Treat,2009,122:337-346. 被引量:1
  • 7Zeng J, Wang L,Li Q,et al. FoxMl is up-regulated in gastric cancer andits inhibition leads to cellular senescence,partially dependent on p27kip. J Pathol,2009’218:419-427. 被引量:1
  • 8王花,李雯.转录因子FoxMl与胰腺导管癌临床病理特征和预后关系的研究.广州:中山大学,2010. 被引量:1
  • 9Wang Z, Ahmad A, Banerjee S,et al. FoxMl is a novel target of a naturalagent in pancreatic cancer. Pharm Res,2010,27 ; 1159-1168. 被引量:1
  • 10Chan DW,Yu SY,Chiu PM,et al. Over-expression of FoxMl transcrip-tion factor is associated with cervical cancer progression and pathogene-sis. Pathol, 2008 ’215 : 245-252. 被引量:1

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部